Pahwa S, Biron K, Lim W, Swenson P, Kaplan M H, Sadick N, Pahwa R
Department of Pediatrics, North Shore University Hospital, Manhasset, NY 11030.
JAMA. 1988 Nov 18;260(19):2879-82.
Acyclovir has become the treatment of choice for varicella-zoster virus (VZV) infections in immunocompromised individuals. This article describes a 4-year-old girl congenitally infected with human immunodeficiency virus who developed a continuous cutaneous infection with VZV that persisted over a 14-month period until her death. Initial episodes of varicella and zoster were responsive to acyclovir treatment; however, subsequent recurrences necessitated administration of multiple courses of acyclovir. Lesions became markedly hyperkeratotic, slow healing, and persistent despite acyclovir therapy. Numerous attempts to isolate virus from the lesions yielded only one isolate late in the course of therapy. This virus clearly demonstrated acyclovir resistance in vitro. Bizarre manifestations of VZV infection could present both diagnostic and therapeutic dilemmas. Prolonged acyclovir treatment of highly immunocompromised patients with acquired immunodeficiency syndrome and severe VZV may lead to the appearance of resistant virus.
阿昔洛韦已成为免疫功能低下个体水痘-带状疱疹病毒(VZV)感染的首选治疗药物。本文描述了一名先天性感染人类免疫缺陷病毒的4岁女孩,她发生了VZV持续性皮肤感染,持续了14个月直至死亡。水痘和带状疱疹的初始发作对阿昔洛韦治疗有反应;然而,随后的复发需要多次使用阿昔洛韦疗程。尽管进行了阿昔洛韦治疗,皮损仍明显角化过度、愈合缓慢且持续存在。从皮损中多次尝试分离病毒,仅在治疗后期分离出一株病毒。该病毒在体外明显表现出对阿昔洛韦耐药。VZV感染的奇异表现可能带来诊断和治疗难题。对获得性免疫缺陷综合征且患有严重VZV的高度免疫功能低下患者进行长时间阿昔洛韦治疗可能会导致耐药病毒出现。